[article]
| Titre : |
Economic Evaluation of anti-epileptic Medicines for Autistic Children with Epilepsy |
| Type de document : |
Texte imprimé et/ou numérique |
| Auteurs : |
Aine RODDY, Auteur ; Martin KNAPP, Auteur ; Celso ARANGO, Auteur ; Maria Andreina MENDEZ, Auteur ; James CUSACK, Auteur ; Declan MURPHY, Auteur ; Roberto CANITANO, Auteur ; Bethany OAKLEY, Auteur ; Vinciane QUOIDBACH, Auteur |
| Article en page(s) : |
p.2733-2741 |
| Langues : |
Anglais (eng) |
| Index. décimale : |
PER Périodiques |
| Résumé : |
We examine the cost-effectiveness of treating epilepsy with anti-epileptic medicines in autistic children, looking at impacts on healthcare providers (in England, Ireland, Italy and Spain) and children?s families (in Ireland). We find carbamazepine to be the most cost-effective drug to try first in children with newly diagnosed focal seizures. For England and Spain, oxcarbazepine is the most cost-effective treatment when taken as additional treatment for those children whose response to monotherapy is suboptimal. In Ireland and Italy, gabapentin is the most cost-effective option. Our additional scenario analysis presents the aggregate cost to families with autistic children who are being treated for epilepsy: this cost is considerably higher than healthcare provider expenditure. |
| En ligne : |
https://doi.org/10.1007/s10803-023-05941-8 |
| Permalink : |
https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=533 |
in Journal of Autism and Developmental Disorders > 54-7 (July 2024) . - p.2733-2741
[article] Economic Evaluation of anti-epileptic Medicines for Autistic Children with Epilepsy [Texte imprimé et/ou numérique] / Aine RODDY, Auteur ; Martin KNAPP, Auteur ; Celso ARANGO, Auteur ; Maria Andreina MENDEZ, Auteur ; James CUSACK, Auteur ; Declan MURPHY, Auteur ; Roberto CANITANO, Auteur ; Bethany OAKLEY, Auteur ; Vinciane QUOIDBACH, Auteur . - p.2733-2741. Langues : Anglais ( eng) in Journal of Autism and Developmental Disorders > 54-7 (July 2024) . - p.2733-2741
| Index. décimale : |
PER Périodiques |
| Résumé : |
We examine the cost-effectiveness of treating epilepsy with anti-epileptic medicines in autistic children, looking at impacts on healthcare providers (in England, Ireland, Italy and Spain) and children?s families (in Ireland). We find carbamazepine to be the most cost-effective drug to try first in children with newly diagnosed focal seizures. For England and Spain, oxcarbazepine is the most cost-effective treatment when taken as additional treatment for those children whose response to monotherapy is suboptimal. In Ireland and Italy, gabapentin is the most cost-effective option. Our additional scenario analysis presents the aggregate cost to families with autistic children who are being treated for epilepsy: this cost is considerably higher than healthcare provider expenditure. |
| En ligne : |
https://doi.org/10.1007/s10803-023-05941-8 |
| Permalink : |
https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=533 |
|
Economic Evaluation of anti-epileptic Medicines for Autistic Children with Epilepsy in Journal of Autism and Developmental Disorders, 54-7 (July 2024)
